Abstract
The stress-activated protein kinase (SAPK) and mitogen-activated protein kinase (MAPK) subfamilies are crucial to environmental stress responses and responses to growth factors that cause transcriptional activation of genes required for cell proliferation, differentiation and programmed cell death. Small molecular compounds with specific structure/activity characteristics have been developed that competitively block SAPK/MAPK binding to ATP. Chemically modified compounds based on ATP binding pocket characteristics have improved selectivity and specificity for SAPK/MAPK isoforms. In addition, sitespecific mutagenesis of MAPKs has helped identify the MAPK structures required for binding recognition and selectivity of these inhibitors. A group of extracellular-signal regulated protein kinase (ERK) inhibitors has been constructed based almost exclusively on their ability to inhibit the ERK activation cascade. Inhibitors have been employed in vitro to identify protein targets and mechanism of action of SAPKs/MAPKs. The efficacy of SAPK/MAPK inhibitors in animal models of inflammation, arthritis, heart failure, cancer and neurological degeneration has provided the impetus for using them in human studies of inflammation and in clinical trials.
Keywords: Stress-activated protein kinase, mitogen-activated protein kinase, c-jun-N-amino-terminal kinase, p38 kinase, extracellular signal-regulated kinase, anthrapyrazolone, pyridinyl imidazole, methoxyflavone
Mini-Reviews in Medicinal Chemistry
Title: Small Molecular Weight Inhibitors of Stress-Activated and Mitogen- Activated Protein Kinases
Volume: 6 Issue: 6
Author(s): C. J. Malemud
Affiliation:
Keywords: Stress-activated protein kinase, mitogen-activated protein kinase, c-jun-N-amino-terminal kinase, p38 kinase, extracellular signal-regulated kinase, anthrapyrazolone, pyridinyl imidazole, methoxyflavone
Abstract: The stress-activated protein kinase (SAPK) and mitogen-activated protein kinase (MAPK) subfamilies are crucial to environmental stress responses and responses to growth factors that cause transcriptional activation of genes required for cell proliferation, differentiation and programmed cell death. Small molecular compounds with specific structure/activity characteristics have been developed that competitively block SAPK/MAPK binding to ATP. Chemically modified compounds based on ATP binding pocket characteristics have improved selectivity and specificity for SAPK/MAPK isoforms. In addition, sitespecific mutagenesis of MAPKs has helped identify the MAPK structures required for binding recognition and selectivity of these inhibitors. A group of extracellular-signal regulated protein kinase (ERK) inhibitors has been constructed based almost exclusively on their ability to inhibit the ERK activation cascade. Inhibitors have been employed in vitro to identify protein targets and mechanism of action of SAPKs/MAPKs. The efficacy of SAPK/MAPK inhibitors in animal models of inflammation, arthritis, heart failure, cancer and neurological degeneration has provided the impetus for using them in human studies of inflammation and in clinical trials.
Export Options
About this article
Cite this article as:
Malemud J. C., Small Molecular Weight Inhibitors of Stress-Activated and Mitogen- Activated Protein Kinases, Mini-Reviews in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/138955706777435670
DOI https://dx.doi.org/10.2174/138955706777435670 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design Your Father and Grandfather’s Atrial Fibrillation: A Review of the Genetics of the Most Common Pathologic Cardiac Dysrhythmia
Current Genomics Efficacy and Cardiovascular Safety of SGLT2 Inhibitors
Current Drug Safety The Role of iNOS in Chronic Inflammatory Processes In Vivo: Is it Damage-Promoting, Protective, or Active at all?
Current Molecular Medicine Identification of Candidate Biomarkers of Acute Aortic Dissection
Recent Patents on DNA & Gene Sequences Nutritional Supplements Modulating Metabolic Syndrome Risk Factors and the Prevention of Cardiovascular Disease
Current Nutrition & Food Science Renal Nerve Ablation for Hypertensive Patients with Chronic Kidney Disease
Current Vascular Pharmacology Telemedicine, Genomics and Personalized Medicine: Synergies and Challenges
Current Pharmacogenomics and Personalized Medicine PI3K/Akt/JNK/c-Jun Signaling Pathway is a Mediator for Arsenite- Induced Cyclin D1 Expression and Cell Growth in Human Bronchial Epithelial Cells
Current Cancer Drug Targets Therapeutic Potential and Mechanisms of Action of Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome
Current Stem Cell Research & Therapy Altered Calmodulin Degradation and Signaling in Non-Neuronal Cells from Alzheimer’s Disease Patients
Current Alzheimer Research Individual Differences in the Neurobiology of Social Stress: Implications for Depression-Cardiovascular Disease Comorbidity
Current Neuropharmacology Novel Therapies Targeting Cardioprotection and Regeneration
Current Pharmaceutical Design Bone Tissue Regeneration - Application of Mesenchymal Stem Cells and Cellular and Molecular Mechanisms
Current Stem Cell Research & Therapy Editorial from Guest Editor [Hot topic: Novel Inflammatory Biomarkers in Diseases (Guest Editor: Yu Chen)]
Inflammation & Allergy - Drug Targets (Discontinued) Editorial (Thematic Issue: Experimental Pharmacological Targets for the Treatment of Cardiac Arrhythmias: Beyond the Vaughn-Williams Classification)
Current Medicinal Chemistry Peptidyl Fluoro-Ketones as Proteolytic Enzyme Inhibitors
Current Topics in Medicinal Chemistry Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Current Pharmaceutical Design Alzheimers Disease: From Pathogenesis to Disease-Modifying Approaches
CNS & Neurological Disorders - Drug Targets Cell-penetrating Peptides as Nucleic Acid Delivery Systems: From Biophysics to Biological Applications
Current Pharmaceutical Design